Purification and Inhibitor Screening of the Full-Length SARS-CoV-2 Nucleocapsid Protein
Molecules · 2025
DOI: 10.3390/molecules30132679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Chen Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus Nucleocapsid Proteins, Antiviral Agents. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Sichuan, Natural Science Foundation of Southwest Medical University, Sichuan Province Science and Technology project.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 has undergone several mutations since 2020, and novel variants continue to emerge to this day. The immune escape ability of the emerging mutants is enhanced and results in robust transmissibility. The neutralizing ability of the antibodies produced in the human body during previous infections is decreased against some of these mutants, which poses a severe challenge to the preventive and therapeutic effectiveness of vaccines and antibody drugs. The nucleocapsid protein is one of the main structural proteins of the coronavirus and plays an important role in the life cycle of the novel coronavirus. This protein is one of the key targets for drug development, and the first major step in drug development is to obtain pure nucleocapsid proteins. However, since nucleocapsid proteins have a nucleic acid-binding function and automatically undergo liquid–liquid phase separation and agglomeration, the purification of full-length nucleocapsids is challenging. In this context, a set of easy-to-operate processes was developed in this study for the purification of nucleocapsid proteins. Finally, a pure full-length nucleocapsid protein without nucleic acid contamination was obtained, which exhibited significantly enhanced accessibility for structural and functional virological studies, vaccine development, and related research applications. Further, the nucleic acid-binding domain of the nucleocapsid protein was targeted, and potential severe acute respiratory syndrome coronavirus 2 inhibitors were identified using virtual screening and biolayer interferometry technology. Notably, the eukaryotically expressed nucleocapsid protein demonstrated a significantly greater binding affinity for Light Green SF Yellowish (KD = 119.7 nM) compared to that demonstrated by its prokaryotic counterpart (KD = 19.9 × 103 nM). The findings of this study suggest the importance of considering both protein source and post-translational modifications of the target proteins to be used in drug screening workflows. Therefore, this compound not only represents a novel therapeutic candidate for COVID-19 but also a critical tool for elucidating antiviral mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.
ORCID-Profile: Shujun Zhang
Förderung
- Natural Science Foundation of Sichuan
- Natural Science Foundation of Southwest Medical University
- Sichuan Province Science and Technology project
- Joint Project of Luzhou Science and Technology Bureau and Southwest Medical University
- College Student Innovation and Entrepreneurship Training Program
- Sichuan Provincial Natural Science Foundation
- Southwest Medical University Natural Science Foundation
- Sichuan Provincial Science and Technology Program
Zitieren
APA
Chen, C., Zhang, Z., Zheng, Q., Zhou, Y., & Zhang, S. (2025). Purification and Inhibitor Screening of the Full-Length SARS-CoV-2 Nucleocapsid Protein. Molecules. https://doi.org/10.3390/molecules30132679
Vancouver
Chen C, Zhang Z, Zheng Q, Zhou Y, Zhang S. Purification and Inhibitor Screening of the Full-Length SARS-CoV-2 Nucleocapsid Protein. Molecules. 2025. doi:10.3390/molecules30132679
BibTeX
@article{Chen2025,
author = {Chen, Chen and Zhang, Zhengfu and Zheng, Qiao and Zhou, Yingshun and Zhang, Shujun},
title = {Purification and Inhibitor Screening of the Full-Length SARS-CoV-2 Nucleocapsid Protein},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30132679}
}
EUVIMED